

# Healthier Hospital Environment



Safer Hospitals

# Hospital Indoor Air Quality A Patient's Death Threat


## The Hospital acquired infection scenario

Studies on hospital acquired infections began more than 150 years ago with Ignaz Semmelweis<sup>1</sup> and Florence Nightingale<sup>2</sup> and contributed to the advance of microbiologic and prophylactic actions in hospital environments. Despite the increase of asepsis practices, hospital infections are still considered a public health concern.

## Hospital indoor air, a micro-organism contamination mean

Many studies<sup>6,7,8</sup> show that bio-aerosols (microorganism conglomerates in suspension in the air) play an important role on the acquisition of infections being calculated as responsible for 10 to 20% of those cases.<sup>6</sup>

The pathogens can be sprayed in many ways, via natural or forced ventilation system, water spray, skin scales released by patients and medical staff, coughing and sneezing<sup>6</sup>. Studies also show that surgical staff members can liberate between 1,500 to 50,000 bacteria per minute<sup>9</sup> and those pathogens may stay in suspension in the air for long periods of time. Studies reveal that 80 to 90% of all surgical wound infections are related to bad air quality and that cleaner air translates into in lower infection risk.



## To prevent is better than to remedy

Hospital infections not only result in high financial cost but also in high number of lost lives. Therefore, better than the clinical treatment itself, the prevention of hospital infections is the best strategy as being cheaper and more effective.

The annual cost of treatment and hospitalization in England accounts for £1bn. According to the NAO (National Audit Office) 2000 report, the NHS could have saved £150m if preventive actions involving hospital hygiene and infection control had been taken.

## Some important pathogens

### Staphylococcus

“Staphylococcus aureus” is the most common bacteria in hospital infections across the world<sup>9</sup> and are especially linked to surgical wound infections<sup>10</sup> that represent 11% of all nosocomial infections in England.

Other bacterial pathogens have high relevance in airborne transmitted diseases and are well studied like the “Streptococcus spp” and “Pseudomonas aeruginosa”. Airborne pathogens are commonly related to respiratory tract infections which correspond to 23% of all hospital infections in England.

### Aspergillus

“Aspergillus spp” is the most common fungus acquired through air transmission in hospitals.

The “conidius propagulus” small size allows it to be in suspension in the air for long periods of time, remaining viable for months, even in low humidity places.<sup>13</sup> Studies estimate that 75% of the Invasive “Aspergillosis” cases result in death, especially due to the difficulty in diagnosing it. The daily therapy cost is extremely high over £701, resulting in an average therapy cost of £9.814(\*) per patient. The therapy cost of just one invasive “Aspergillosis” patient is approximately equivalent to 60 Airfree units

\*considering a 70 kg patient. Approximate cost of AWP (of Lamb) is US\$188 per 50mg vial. Typical dose is 5.0 mg/kg/day. Estimated daily cost per patient US\$1,316.

## Airfree<sup>®</sup> proven efficiency

Airfree air purifier is proven to drastically reduce the airborne microbial charge.

In many microbiologic tests in real life conditions performed by ISO 17025 certified independent laboratories, Airfree airborne bacterial and fungal charge reduction in the environment is close to 90%. Airfree reduces toxic ozone as well.

The extraordinary efficiency of patented Airfree technology combines excellent thermo dynamics in conjunction with the high efficiency of its ceramic core that captures and incinerates airborne microorganisms at temperatures around 200 °C. In fact, just 41°C is required to denaturize a series of thermo-sensitive proteins found in many cell regions, especially in the nucleus.<sup>19</sup> Independent tests show that Airfree can reduce up to 96% of the number of airborne bacteria and fungus in 46m<sup>2</sup> contaminated rooms with people working in it.

### Airfree additional advantages

- Destroys microorganisms regardless of its virulence and size
- Reduces toxic ozone
- Totally silent, does not disturb patients
- No maintenance required, no toxic filters to replace
- No installation required, "plug in" unit
- Low purchase and operating cost

It is reasonable to presume that given Airfree extraordinary airborne bacteria and fungus contamination reduction rate a wide number of infections could be avoided with the installation of Airfree.

# Airfree® P models

**Efficient:** Airfree is tested in real working environments with people in them by credible ISO 17025 independent laboratories and universities in several countries. Airfree destroys any microorganism such as mould spores, bacteria, viruses, and dust mite allergens when passing through its patented high efficiency thermodynamic sterilising ceramic core regardless of how hazardous and small they might be.

**Silent:** No sound emission.

**Exclusive:** Airfree uses just heat Thermodynamic technology to destroy and incinerate airborne microorganisms. No fiber glass filters, triclosan coated paper or any kind of material that can be harmful to those operating or wasting it.

**Ozone Reduction:** Airfree exclusive Thermodynamic technology is the only one reducing ozone while destroying microorganisms.

**Economic:** Airfree model electric consumption is lower than a 50W light bulb. No replacement parts required like filters that may cost hundreds of dollars a year.


**Easy Installation:** Just place Airfree on the floor and plug it into the nearest electric outlet. No need for maintenance or special cleaning.



## Bibliographical References


1. Rea E., Upshur R. Semmelweis revisited: the ethics of infection prevention among health care workers. *CMAJ*, 2001; 164 (10):1447- 1448.
2. Gallagher R. Infection control: public health, clinical effectiveness and education. *Br J Nurs.*, 1999;8(18):1212-14.
3. Pannuti CS, Grinbaum RS. An overview of nosocomial infection control in Brazil. *Infect Control Hosp Epidemiol.* 1995 Mar;16(3):170-4.
4. ANVISA. Curso Básico de Controle de Infecção Hospitalar. Brasília, 2000.
5. Hoeffel et al. Controle e prevenção de infecções – custos e economia. Jan., 2005. <http://www.cih.com.br/custos.htm#11>
6. Beggs CB. The airborne transmission of infection hospital buildings: fact or fiction? *Indoor and Built Environment*, 2003;12:9-18.
7. Beggs CB. Engineering the control of airborne pathogens. School of Civil Engineering, University of Leeds, Leeds LS2 9JT, UK.
8. Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenem-resistant *Pseudomonas aeruginosa*: a comparative analysis of two case-control studies in hospitalized patients. *Journal of Hospital Infection*, 2005;59(2):96-101.
9. Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A, Jones RN. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY antimicrobial surveillance program. *Braz J Infect Dis vol.5 no.4 Salvador Aug.* 2001.
10. Trindade, P. A., McCulloch, J. A., Oliveira, G. A., Mamizuka, E. M. Molecular Techniques for MRSA Typing: Current Issues and Perspectives. *The Brazilian Journal of Infectious Diseases.*, 2003;7(1):32-43.
11. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States. 1980-1990. National Nosocomial Infections Surveillance System. *J Infect Dis.* 1993;167:1247-1251.
12. Maschmeyer G, Ruhnke M. Update on antifungal treatment of invasive *Candida* and *Aspergillus* infections. *Mycoses.*, 2004;47(7):263-76.
13. Warris A, Voss A, verwij PE., Hospital sources of *Aspergillus* species: New routes of transmission? *Rev Iberoam Micol*, 2001, 18:156-162.
14. Richardson MD & Ellis M.. Clinical and laboratory diagnosis of systemic fungal infection. *Hospital Medicine*, 2000; 61: 610-614.
15. Brochura médica de divulgação medicamento V-Fend da Pfizer - 2004.
16. Lacerda RA. Infecções Hospitalares no Brasil. Tese de Doutorado, USP – Departamento de Enfermagem, 1995.
17. Starling CE, Couto BR, Pinheiro SM. Applying the Centers for Disease Control and Prevention and National Nosocomial Surveillance system methods in Brazilian hospitals. *Am J Infect Control.*, 1997; 25(4):303-11.
18. Lepock JR. Role of nuclear protein denaturation and aggregation in thermal radiosensitization. *Int J Hyperthermia.* 2004 Mar;20(2):115-30.
19. Lepock JR. Cellular effects of hyperthermia: relevance to the minimum dose for thermal damage. *Int J Hyperthermia.* 2003 May-Jun;19(3):252-66.
20. Consulta Pública 109 / 2003

## See the strawberries 10 day test\*:



\*test made in two equal closed rooms

### Airfree Efficiency Test: microorganism reduction



Test performed by SGS Natec - Germany - Test M00-4990  
ISO 17025 Independent Laboratory

See the complete list of test reports at:  
[www.airfree.com](http://www.airfree.com)

Microbiologic content supervised by Cristiane Minussi, USP biologist.

